Keros Therapeutics, Inc. (NASDAQ:KROS) traded at $71.08 at last check on Friday, Nov 20, making an upward move of 2.29% on its previous day’s price.
Looking at the stock we see that its previous close was $69.49 and the beta (5Y monthly) reads 0 with the day’s price range being $69.35 – 74.00. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, KROS has a high of $74.6 and a low of $19.1. The company’s stock has gained about 34.9% over that past 30 days.
Based on estimates by 4 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Keros Therapeutics, Inc. (KROS) stock as a Hold, while 4 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the KROS stock currently stands at 0, and the current price level is 21.89% off its SMA20 and 42.66% from its 50-day simple moving average. The RSI (14) is pointing at 73.42 while the volatility over the past week is 10.55% and jumps to 11.85% over the past one month. The beta value is 0, while the average true range (ATR) is currently pointing at 6.25. The average price target for the stock over the next 12 months is $59.25, with the estimates having a low of $42 and a high of $75. These price ends are -40.91% and +5.51% off the current price level respectively, although investors could be excited at the prospect of a -15.59% if the KROS share price touches on the median price of $60.
Let’s briefly compare Keros (KROS) stock to its peers. We find that today’s price change of +2.29% and 0% over the past 12 months for KROS competes that of Bristol-Myers Squibb Company (BMY), which has seen its stock price fall -0.77% in the latest trading session and is +8.37% over the last one year. Another of its peers Amgen Inc (AMGN) has dropped -0.67% today, but is -2.04% down over the past year, while Gilead Sciences Inc (GILD) is also up 2.29% yet its price remains in the red at 0% over the same period. Bristol-Myers has a P/E ratio of 0 compared to Keros 0 and Amgen’s 17.99. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -0.68% and -0.75%, respectively, in early deals.
Coming back to Keros Therapeutics, Inc. (NASDAQ:KROS), we note that the average 3-month trading volume was 150.69 Million, while that of the preceding 10-day period stands at 383.02 Million. Current shares outstanding are 23.18 Million.
According to data from Thomson Reuters, insiders hold 14.9% of the company’s shares while institutions hold 71.34%. The data shows that short shares as of October 29, 2020, stood at 780.07 Million at a short ratio of 4.76. This represents a 3.86% Short interest in Shares outstanding on October 29, 2020. Shares short rose in October from the previous month at 318.48 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +253.98% up in year-to-date price movement.